Health 12 May 2026 - 26 May 2026

DiaMedica Shares Down Ahead of Stroke Trial Update
····

DiaMedica Shares Down Ahead of Stroke Trial Update

DiaMedica Therapeutics Inc. shares fell Tuesday, with the drug developer closing lower as the major indexes gained. The stock was last at $5.77 after hours, off 6 cents from its close. It traded between $6.29 and $5.56 earlier in the session. Volume reached about 152,000 shares. Market cap was roughly $311 million. DiaMedica is heading into a catalyst week as it prepares to present at 3:45 p.m. ET Thursday during the Jefferies Global Healthcare Conference in New York. The event, which runs June 2-4, draws attention from healthcare investors looking for pipeline news and signs of financing.
June 2, 2026
INVO Fertility Stock Slides After Filing Delay
····

INVO Fertility Stock Slides After Filing Delay

INVO Fertility Inc. shares slipped early Tuesday, missing out on a stronger U.S. market while traders looked for updates on late regulatory filings. The company, listed on Nasdaq as IVF, dropped 2.4% to $1.60. The stock opened at $1.55 and hit $1.64 at session highs, market data showed. INVO stock trades without key financials in place. The company told the SEC on May 18 it couldn’t file its Form 10-Q since its annual Form 10-K for 2025 still wasn’t done. The quarterly update is what public companies use to report results to investors.
May 26, 2026
Lexaria Gets Attention with GLP-1 Test on Deck
····

Lexaria Gets Attention with GLP-1 Test on Deck

Lexaria Bioscience Corp. will open for normal Nasdaq trading on Tuesday after closing Friday at $0.65. Shares climbed 7.33% in the last full session before the Memorial Day holiday. Regular trading restarts at 9:30 a.m. Eastern, with pre-market open at 4 a.m. Lexaria’s move is now in focus as its next test takes aim at the fast-growing oral obesity drug space. GLP-1 medicines that copy a gut hormone for hunger and blood sugar are a big market, dominated by Novo Nordisk and Eli Lilly.
May 26, 2026
Afya shares hover at $14, next move eyed as market reopens Tuesday
····

Afya shares hover at $14, next move eyed as market reopens Tuesday

Afya Limited stock stuck around $14 as the new trading week kicked off, with the Brazilian medical education company finishing last week nearly unchanged. U.S. exchanges were closed Monday for Memorial Day. Tuesday’s market open is shaping up as the next check for the Nasdaq-listed stock. Afya hasn’t had much new news to drive trading since it posted first-quarter numbers earlier this month. Now investors are weighing steady cash flows and a buyback against thinner margins and some uncertainty on digital medical product growth.
May 25, 2026
Paysign Shares Surge Nearly 20% This Holiday Week as Pharma Payments Get Attention
····

Paysign Shares Surge Nearly 20% This Holiday Week as Pharma Payments Get Attention

Paysign Inc. is up for a fifth straight session heading into the Memorial Day holiday, after shares bounced back from a rough earnings move earlier in the month. U.S. markets are closed Monday for Memorial Day, and Nasdaq notes May 25 as a non-trading day. Paysign finished Friday at $6.72, rising 6.0% on the session. Shares are up roughly 19.6% from the May 15 close of $5.62, according to market data. This bounce comes after a 12.3% slide on May 13, right after Paysign posted first-quarter numbers. The stock then saw steady buying ahead of the holiday.
May 25, 2026
Molecular Partners Stock Pops Into Holiday Pause as Traders Eye Cancer-Drug Data
····

Molecular Partners Stock Pops Into Holiday Pause as Traders Eye Cancer-Drug Data

Molecular Partners AG goes into a closed-market Monday with momentum but no fresh trading: its SIX-listed shares last closed at CHF 3.15 on Friday, up 9.38%, after touching an intraday high of CHF 3.19. The move left the stock still below its 52-week high of CHF 3.96 and above the CHF 2.66 low set on May 13. The pause matters. SIX Swiss Exchange is shut on May 25 for Whit Monday, while U.S. markets are closed for Memorial Day, leaving Molecular Partners’ Zurich line and Nasdaq ADS without a live Monday price. The company’s own stock page listed the Nasdaq line at $4.18 after Friday trading.
May 25, 2026
Guardant Health jumps 25% in a week as Medicare test looms
····

Guardant Health jumps 25% in a week as Medicare test looms

Guardant Health is coming off a volatile week heading into a holiday break, finishing Friday at $118.95 after a fresh FDA approval helped push the shares up about 25% for the week. The Nasdaq cancer test maker surged 17.1% on May 20 as its Guardant360 Liquid CDx blood test cleared a key regulatory hurdle. Shares reached as much as $121.01 during the week, according to price data. Markets are closed at the moment. May 24 falls on a Sunday in New York, and according to Nasdaq’s 2026 holiday calendar, U.S. equity markets will stay shut for Memorial Day on Monday, May 25. Regular trading picks up again Tuesday, giving investors their first shot to react.
May 24, 2026
Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid
····

Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid

Ocugen Inc. goes into the Monday market holiday stuck around $1.34. Trading was muted for the biotech stock on Friday ahead of the Memorial Day break, with shares showing little movement. Nasdaq traders are off Monday, May 25, for Memorial Day. That means Tuesday is when investors can trade Ocugen shares after last week's moves and look ahead to the company's upcoming ophthalmology events.
May 24, 2026
AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results
····

AAPG Shares Bounce Ahead of ASCO, Investors Eye Drug Results

Ascentage Pharma Group International’s U.S. shares climbed going into the long weekend, after the cancer drug maker put out fresh clinical results before the American Society of Clinical Oncology meeting. That offered investors an update on a pipeline that’s faced pressure most of the past year. The American depositary shares finished at $21.01 on Friday, gaining 35 cents, or 1.69%. The ADSs stayed far from the 52-week high of $48.45, though the stock had dropped to $18.56 earlier in the week.
May 23, 2026
Larimar Shares Fall, FDA Submission Seen as Next Hurdle
····

Larimar Shares Fall, FDA Submission Seen as Next Hurdle

Larimar Therapeutics stock moved lower in late-morning trading Friday as investors watched for a June regulatory update on its top Friedreich’s ataxia treatment. LRMR was down 3.36% to $3.45 at 11:02 a.m. EDT while the market was still open, according to StockAnalysis data. Larimar is aiming to kick off a rolling Biologics License Application for nomlabofusp in June. A BLA is the FDA’s main filing for companies looking to bring a biologic drug to the U.S. market. Accelerated approval means the application could get cleared using a surrogate marker rather than waiting for full results.
May 22, 2026
GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
·····

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist

Structure Therapeutics Inc. shares rose 5.3% to $38.79 in late New York trading on Thursday, outpacing the broader biotech tape as investors kept the drug developer in the obesity-pill trade. The stock touched $38.85, with volume of about 499,000 shares. The move came with no new company release in the past two days. That matters because the next real test for Structure is not a same-day headline, but whether aleniglipron, its experimental oral GLP-1 drug, can move cleanly into Phase 3 and hold up against larger rivals.
May 21, 2026
Aimei Health: Nasdaq Sends AFJK 60-Day Notice
····

Aimei Health: Nasdaq Sends AFJK 60-Day Notice

Aimei Health Technology Co., Ltd is facing a new Nasdaq compliance issue as of Thursday’s U.S. session after the blank-check firm confirmed its March-quarter report was not filed on time. AFJK isn’t a regular healthcare stock right now. It’s a blank-check company set up to buy or merge with another firm. That means listing status, timing on any deal, and how much cash is in its trust are bigger factors than typical revenue trends.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
····

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares barely moved in premarket trading on Nasdaq Thursday. Investors looked past new disclosures and kept their eyes on the upcoming clinical milestone for NGN-401, the lead gene therapy for Rett syndrome. The stock finished Wednesday at $26.95, gaining 7 cents, or 0.3%. It traded in a range from $26.50 to $28.08. Broader markets rallied too, with the Nasdaq Composite adding 1.5% and the Russell 2000 up 2.6% on Wednesday.
May 21, 2026
Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key
····

Jaguar Health Shares Spike After 816% Revenue Jump, But Trial Results Still Key

Jaguar Health Inc. shares rose Wednesday as the small drugmaker posted an 816% surge in first-quarter revenue. The bump came after a licensing deal that transferred U.S. commercial rights for Mytesi and Canalevia-CA1 to Woodward Specialty, which is linked to privately held Future Pak. Shares finished the day at $3.67, gaining 9.2% from $3.36 on Tuesday. Trading volume jumped to 593,152 shares from 69,266, Jaguar’s LSEG-based price table showed.
May 21, 2026
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
····

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3

BioVie Inc. shares rose on Wednesday after the clinical-stage drug developer said its SUNRISE-PD Parkinson’s trial had completed the last patient evaluation visit, moving the story from enrollment and dosing toward data. The stock closed at $1.35, up 3.05%, after trading between $1.31 and $1.37. That matters now because BioVie is a small, low-volume biotech whose valuation is tied closely to clinical events. At Wednesday’s close, the company had a market value of about $10.2 million, and trading volume was 19,735 shares, below the 89,680 average shown by Google Finance.
May 21, 2026
Exelixis Up After Merck Pact Focuses Attention on Cancer Study
·····

Exelixis Up After Merck Pact Focuses Attention on Cancer Study

Exelixis shares climbed Wednesday after the company announced a new Merck partnership, putting its next cancer drug program further into late-stage trials. Shares traded 2.5% higher at $49.89 in the afternoon, putting the Alameda, California-based company’s market cap near $13.3 billion. Biotech stocks were strong, with the iShares Nasdaq Biotechnology ETF up 1.8% and the SPDR S&P Biotech ETF up 3.8%.
May 20, 2026
BAT’s Velo Bet Faces a Fresh WHO Warning After Shares Hit a 52-Week High
····

BAT’s Velo Bet Faces a Fresh WHO Warning After Shares Hit a 52-Week High

Friday brought new pressure from the World Health Organization, which called on governments to strengthen regulation of nicotine pouches—a move that lands just as British American Tobacco p.l.c. hit a 52-week high and accelerated its Velo rollout. The warning adds a fresh twist for the Lucky Strike maker. Now, BAT is counting on its smokeless lineup—Velo pouches, Vuse vapes—to make up for shrinking cigarette demand. But just as BAT leans harder on these products, investors sent tobacco shares higher this week after the U.S. Food and Drug Administration relaxed its enforcement for certain vapes and nicotine pouches still under review.
May 15, 2026
GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK plc is pushing for wider access to bepirovirsen in China, locking in an exclusive deal with Chia Tai Tianqing Pharmaceutical, part of Sino Biopharmaceutical. With this move, the British pharma giant aims to turn its late-stage hepatitis B candidate into a serious growth engine. CTTQ is set to manage import, distribution, hospital access, and promotion across mainland China. GSK, for its part, keeps a grip on regulatory and medical strategy. Timing’s key here. Bepirovirsen is on the investor radar as GSK pushes to move past its traditional vaccine and HIV drug business, aiming to top £40 billion in yearly sales by 2031—a goal it stuck with after posting £7.6 billion for the first quarter. Last month, Chief Executive Luke
May 13, 2026
BAT shares extend rally as FDA shift gives Vuse and Velo a cleaner U.S. read
······

BAT shares extend rally as FDA shift gives Vuse and Velo a cleaner U.S. read

British American Tobacco moved higher in London Wednesday, building on a strong surge that set it apart during Tuesday’s sluggish trading. Shares traded at GBX 4,713.78 according to Google Finance, a 1.72% gain and close to the upper end of the morning’s moves—just shy of the 52-week peak at GBX 4,876.92. Investors reacted after U.S. regulators offered more clarity. The FDA’s latest enforcement guidance signals it won’t be targeting some e-cigarette and oral nicotine pouch products that haven’t secured final authorization yet, as long as their premarket applications are still pending. Those applications—required before companies can legally introduce new tobacco products—remain under review.
May 13, 2026
Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch
····

Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch

SÃO PAULO, May 12, 2026, 14:07 Valneva’s Brazilian partner has secured approval to produce the chikungunya vaccine locally, paving a route for the shot to potentially enter Brazil’s public health system. The update lands as Valneva’s stock faces a turbulent stretch. Anvisa, the national health regulator, authorized Instituto Butantan to handle manufacturing in Brazil. Until now, only Valneva’s own factories had been listed as production sites since the vaccine’s 2025 approval.
May 12, 2026
1 2 3 4 … 6